Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vistusertib and Paclitaxel in Solid Tumours
NCT02193633Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Apr 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in solid tumor, ovarian cancer and squamous cell carcinoma of the lung (LSCC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Maximum Tolerated Dose at 7 weeks. Started Apr 2013; status: completed.
02
Drugs
vistusertib
03
Conditions
solid tumorovarian cancersquamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02193633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193633.